News Related to Glioblastoma

Related coverage linked through entity extraction aliases.

Telix Submits European Marketing Authorization for Brain Cancer Imaging Agent TLX101-Px

Feb 18, 2026

Telix Pharmaceuticals submitted a marketing authorization application in Europe for TLX101-Px, a glioma imaging agent, on February 18, 2026. The filing covers major European markets and a U.S. NDA submission will follow.

FDA Approves Optune Pax Device for Locally Advanced Pancreatic Cancer

Feb 13, 2026

The FDA approved Optune Pax, a wearable Tumor Treating Fields device, for locally advanced pancreatic cancer in combination with gemcitabine and nab-paclitaxel. The approval marks the first new treatment for this indication in nearly 30 years.